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Preoperative palsy score has no significant
association with survival in non-small-cell
lung cancer patients with spinal metastases
who undergo spinal surgery
Yen-Jen Chen1,2,3* , Hsien-Te Chen1 and Horng-Chaung Hsu1,2
Abstract
Background: Survival is a key factor physicians consider when selecting a treatment modality for the treatment of
spinal metastases. Various assessment systems can predict length of survival and facilitate selection of the most
appropriate treatment. Spinal palsy is a prognostic parameter in the Tokuhashi scoring system but not in the
Tomita scoring system. A limitation of these scoring systems is that studies of them have included different tumor
types. The aim of this study was to evaluate the usefulness of preoperative neurological status as a prognostic
factor in non-small-cell lung cancer patients with spinal metastases who underwent surgical treatment.
Methods: From November 2000 to March 2010, 50 patients with symptomatic metastatic spinal cord compression
secondary to non-small-cell lung cancer underwent palliative surgery. Data collected included patient age and sex,
tumor histology, date of surgery, death or last follow-up, preoperative and postoperative ambulatory status according
to the Frankel grading system, body mass index (BMI), number of vertebra involved, number of other bone metastasis,
visceral metastasis, and preoperative Karnofsky performance status. Log-rank test and multivariate Cox proportional
hazard regressions were used to evaluate possible prognostic factors.
Results: The mean patient age was 61.6 years (range, 20–87 years), and 34 were male and 16 were female. The
median postoperative survival time was 7.5 months. The median survival was 2.5 months (95 % confidence
interval (CI): 1.22–16.3 months) in the Frankel A + B group and 8.0 months (95 % CI: 5.52–9.89 months) in the
Frankel C + D group (p = 0.87). Multivariate Cox proportional hazard regressions showed that preoperative
performance status was significantly associated with survival. Preoperative palsy score had no statistically
significant association with survival.
Conclusions: Preoperative palsy score had no statistically significant association with survival in non-small-cell
lung cancer patients with spinal metastases who underwent spinal surgery in this study.
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Background
As advances in chemotherapy prolong the life expect-
ancy of patients with solid tumors, the frequency of
spinal metastases is likely to increase. Survival is a key
factor physicians consider when selecting a treatment
for spinal metastases. Various assessment systems can
predict the length of survival and facilitate the selection
of the most appropriate treatment. The assessment sys-
tems, however, differ with respect to the parameters
assessed and the significance assigned to each parameter
in the total score. Spinal palsy is one of the prognostic
parameters in the Tokuhashi scoring system [1, 2] but is
not included in the Tomita scoring system [3]. A limita-
tion of these scoring systems is that studies examining
them have included different tumor types.
The aim of this study was to evaluate the usefulness of
preoperative neurological status as a prognostic factor in
non-small-cell lung cancer patients with spinal metasta-
ses who underwent surgical treatment.
Material and methods
Patients
From November 2000 to March 2010, 50 patients with
symptomatic metastatic spinal cord compression second-
ary to non-small-cell lung cancer underwent palliative sur-
gery. A retrospective review of the hospital records and
radiographs of these patients was conducted. The indica-
tion for surgery was neurologic deficit due to spinal cord
compression. A single surgeon performed all the surgeries.
The Research Ethics Committee (China Medical Univer-
sity & Hospital, Taichung, Taiwan) approved this retro-
spective analysis (No. DMR101-IRB2-310).
All patients presented with weakness in the lower ex-
tremities, and 10 patients (20 %) remained ambulatory.
The Frankel grading system [4] and a supplementary
ambulatory status score were used during the preopera-
tive and postoperative periods to evaluate neurologic
status. Preoperative evaluations included plain radio-
graphs and magnetic resonance imaging (MRI) or com-
puted tomography (CT).
Surgical interventions
A total of 55 surgical procedures were performed on the
50 patients, and 46 patients underwent a single operation.
Three patients underwent primary surgery for metastatic
spinal cord compression, followed by a second operation
for noncontiguous metastases. One patient underwent 3
additional procedures because of repeated local recur-
rences over a 3-year period.
Three patients underwent combined anterior and pos-
terior procedures (anterior corpectomy, reconstruction
with polymethylmethacrylate, and posterior instrumenta-
tion). Two patients with cervical spine metastases under-
went anterior surgery. The remaining 45 (90 %) patients
underwent a posterolateral transpedicle approach (PTA).
All patients underwent spinal instrumentation following
adequate decompression. Local radiotherapy, systemic
chemotherapy, and/or targeted therapy were performed
after wound healing, usually 3–4 weeks after surgery.
Factors for analysis
Data collected included patient age and sex, tumor hist-
ology, date of surgery, death or last follow-up, preopera-
tive and postoperative ambulatory status according to
the Frankel grading system, body mass index (BMI),
number of vertebra involved, number of other bone me-
tastasis, visceral metastasis, and preoperative Karnofsky
performance status. Overall survival was calculated from
the date of surgery to the date of death.
Factors included in the analyses were sex, age (≤54,
55–74, and ≥75 years), tumor type (adenocarcinoma or
nonadenocarcinoma), preoperative and postoperative
palsy score (Frankel A + B vs. Frankel C + D vs. Frankel E),
BMI (underweight vs. eutrophic vs. overweight/obese),
number of vertebra involved (<3 vs. ≥3), other bone me-
tastasis (without vs. with), visceral metastasis (without vs.
with), and preoperative Karnofsky performance status
(10–40 % vs. 50–70 % vs. 80–100 %).
Statistical analysis
Survival curves were plotted using the Kaplan-Meier
method, and the significance of the differences between
groups was determined using a log-rank test that consid-
ered the effects of age. The median survival time and
95 % confidence interval (CI) were then estimated based on
the Brookmeyer and Crowley method [5]. A p value <0.05
was considered statistically significant. Chi-squared test sta-
tistics and p values were calculated based on the log-rank
test of specific pairs. For variables with 2 subgroups, a
p < 0.05 was considered statistically significant. For vari-
ables with 3 subgroups, a p < 0.0167 was considered sta-
tistically significant (the Bonferroni correction method
was used to suppress a spurious significant difference).
Univariate and multivariate Cox proportional hazard
regressions were used to detect possible prognostic fac-
tors. To investigate the most significant factors, factors
Table 1 Post-operative complications






Sigmoid colon perforation 1
30-day mortality 2
CSF cerebrospinal fluid
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significantly impacted with survival in univariate ana-
lysis were included in multivariate analysis. Pre-op palsy
score was considered to be the important factor, so it
was included in multivariate analysis even no signifi-
cance in univariate analysis. A p < 0.05 was considered
statistically significant. All analyses were performed
using SAS 9.1 statistical software (SAS Institute, Inc,
Cary, NC, USA).
Results
The mean patient age was 61.6 years (range, 20–87 years),
and there were 34 males and 16 females. The tumor sites
included the thoracic spine (n = 28), lumbar spine (n = 12),
thoracolumbar spine (n = 6), cervical spine (n = 3), and
sacrum (n = 1). Adenocarcinoma (32 patients) was the
most common histological type, followed by squamous
cell carcinoma (9 patients). The mean intraoperative blood
loss volume was 975 mL (range, 350–6500 mL), and the
mean surgical time was 4.8 h.
Neurologic improvement by ≥1 Frankel grade was
noted in 37 of the 50 cases (74 %). Twelve patients
showed no improvement, and 1 patient showed deterior-
ation from Frankel grade B to grade A. Overall, 68 % of
patients (34/50) were ambulatory after surgery. Twenty-
Fig. 1 Kaplan-Meier survival curve of the 50 lung cancer patients with spinal metastases who underwent spinal surgery
Fig. 2 Kaplan-Meier survival curve of the 50 patients with pre-operative Tokuhashi palsy score 0 vs score 1 (p = 0.87)
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two of 40 (55 %) nonambulatory (Frankel B/C) patients
became ambulatory (Frankel D/E).
One patient developed symptomatic tumor recurrence
at the level of previous decompression, and 3 patients
developed new symptomatic spinal cord compressions
because of noncontiguous metastases. These patients
underwent repeat decompressive surgeries.
Of 12 observed complications (Table 1), 11 were surgery
related. There was no intraoperative mortality; however, 3
patients died during the postoperative period. One patient
died from respiratory failure 14 days after surgery, 1 died
from hepatic and respiratory failure 23 days after surgery,
and 1 died from nonsurgery-related sigmoid colon perfor-
ation and sepsis 37 days after surgery. The median postoper-
ative survival time was 7.5 months (95 % CI: 4.2–
10.9 months). The Kaplan-Meier curve (Fig. 1) showed that
58 % (29/50) of the patients survived >6 months. The Fran-
kel A + B group (palsy score 0 in Tokuhashi system) con-
tained 8 patients, and the Frankel C +D group (palsy score
1 in Tokuhashi system) contained 42 patients. The median
survival was 2.5 months (95 % CI: 1.22–16.3 months) in the
Table 2 Kaplan-Meier survival curve estimates for analysis of








≤54 16 9.5 (3.22–11.07)
55–74 24 8.7 (3.09–13.14)
≥75 10 3.7 (2.0–5.52)
Sex 0.220
M 34 6.3 (3.09–9.13)
F 16 11.1 (5.52–13.86)
Tumor histology 0.003*
Adenocarcinoma 32 9.9 (7.43–11.20)
Non-adenocarcinoma 18 3.5 (2.20–5.39)
Pre-op palsy score 0.870
0 (Frankel 1, 2) 8 2.5 (1.22–16.03)
1 (Frankel 3, 4) 42 8.0 (5.52–9.89)
Post-op palsy score <0.001*
0 (Frankel 1, 2) 2 2.4 (2.4–2.4)b
1 (Frankel 3, 4) 32 5.5 (2.92–7.33)
2 (Frankel 5) 16 14.3 (9.23–17.02)
Pre-op PS <0.001*
Poor (0, PS 10–40 %) 8 2.4 (0.46–3.78)
Moderate (1, PS 50–70 %) 20 3.7 (2.4–6.3)
Good (2, PS 80–100 %) 22 13.1 (9.23–16.03)
BMI 0.540
Underweight (1) 5 6.3 (0.59–12.02)
Eutrophic (2) 31 6.0 (3.18–8.91)
Overweight/obese (3) 14 9.1 (7.62–10.65)
Number of vertebra involved 0.630
<3 24 6.3 (3.15–9.46)
≥3 26 9.1 (3.16–15.11)
Other bone metastasis 0.818
Without 20 5.4 (1.25–9.46)
With 30 8.7 (6.56–10.85)
Visceral metastasis 0.567
Without 40 8.0 (5.53–10.51)
With 10 3.2 (0–7.65)
*Significant at p value <0.05
ap value is calculated based on log-rank test over all stratification and takes
the effect of age into consideration
bThe 95 % CI may be problematic due to too few data values
PS performance status, CI confidence interval, BMI body mass index
Table 3 Pairwise comparisons of survival between subgroups
Variable Chi-square p value
Histology
Adeno vs Non-adeno 8.7 0.003*
Sex
F vs M 1.5 0.220
Age (year)
≤54 vs 55–74 0.19 0.660
≤54 vs ≥75 7.3 0.007*
55–74 vs ≥75 6.41 0.010*
Pre-op PS
0 vs 1 0.45 0.500
0 vs 2 13.44 <0.001*
1 vs 2 13.99 <0.001*
Pre-op palsy
0 vs 1 0.027 0.870
Post-op palsy
0 vs 1 1.95 0.160
0 vs 2 6 0.010*
1 vs 2 9.12 0.003*
BMI
1 vs 2 0.02 0.878
1 vs 3 1.07 0.301
2 vs 3 0.97 0.324
Number of vertebra involved
<3 vs ≥3 0.23 0.630
Other bone metastasis
Without vs with 0.05 0.818
Visceral metastasis
Without vs with 0.33 0.567
*Significant at p-value <0.05
Adeno adenocarcinoma, Non-adeno non-adenocarcinoma, PS performance status,
BMI body mass index, BMI 1 underweight, 2 eutrophic, 3 overweight/obese
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Frankel A +B group and 8.0 months (95 % CI: 5.52–
9.89 months) in the Frankel C +D group (Fig. 2; p = 0.87).
Log-rank test (Table 2) and pairwise comparisons
of survival between subgroups (Table 3) showed that
age <75 years, adenocarcinoma histology, higher preopera-
tive performance status score, and higher postoperative
palsy score were all significantly associated with longer
survival. Sex, BMI, number of vertebra involved, other
bone metastasis, visceral metastasis, and preoperative
palsy score had no statistically significant association with
survival.
Multivariate Cox proportional hazard regressions fur-
ther showed that only higher preoperative performance
status score had a statistically significant association with
longer survival (Table 4).
Discussion
Tokuhashi et al. [2] stated that the average survival period
was longer (10.4 ± 13.6 months) in patients without neuro-
logic deficits than in patients with complete palsy (3.7 ±
3.9 months). Therefore, they included “spinal cord palsy”
as a prognostic parameter in their study. Several authors
have reported that patients with paralysis at presentation
or posttreatment have a considerably shorter life expect-
ancy than ambulatory patients [6–10]. Prasad and Schiff
[11] reported that other than the nature of the primary
tumor, the presence of paraparesis prior to surgery had
the most detrimental effect on survival.
In 2001, Tomita et al. [3] developed a scoring system
that does not use neurologic status as a prognostic factor
for survival in patients with spinal metastases. The au-
thors described that a long survival period can be pos-
sible with appropriate treatment, even in cases with
paraplegia, and suggested that spinal cord decompression
can improve paralytic conditions. Patients with paralysis
tend to have shorter survival because of cancer progres-
sion and not due to the paralysis itself [3]. Spiegel et al.
[12] reported that neurologic deficits did not significantly
influence survival of melanoma patients. North et al. [13]
observed that the preoperative ambulatory status
Table 4 Univariate and multivariate Cox proportional hazard regressions Model
Univariate Multivariate
Variable Hazard ratio (95 % CI) p value Hazard ratio (95 % CI) p value
Sex
F (ref: M) 0.61 (0.33–1.14) 0.120
Age (year)
55–74 (ref: ≤54) 1.16 (0.6–2.25) 0.659 0.78 (0.37–1.64) 0.512
≥75 (ref: ≤54) 3.28 (1.37–7.82) 0.008* 1.22 (0.37–4.05) 0.748
BMI (kg/m2)
Eutrophic (ref: underweight) 1.03 (0.39–2.68) 0.958
Overweight (ref: underweight) 0.72 (0.25–2.05) 0.538
Pre-op palsy
1 (ref: 0) 1.18 (0.49–2.83) 0.706 1.23 (0.5–3.03) 0.653
Post-op palsy
1 (ref: 0) 0.3 (0.06–1.36) 0.119
2 (ref: 0) 0.1 (0.02–0.51) 0.006*
PS score
1 (ref: 0) 0.43 (0.18–1.03) 0.059 0.52 (0.16–1.74) 0.289
2 (ref: 0) 0.09 (0.03–0.26) <0.001* 0.14 (0.03–0.54) 0.004*
Histology
Adeno (ref: Non-adeno) 0.38 (0.2–0.71) 0.003* 0.59 (0.28–1.25) 0.167
Number of vertebra involved
≥3 (ref: <3) 0.7 (0.39–1.25) 0.228
Other bone metastasis
With (ref: without) 0.83 (0.46–1.49) 0.531
Visceral metastasis
With (ref: without) 1.08 (0.52–2.23) 0.837
*Significant at p-value <0.05
PS performance status, CI confidence interval, ref reference, Adeno adenocarcinoma, Non-adeno non-adenocarcinoma, BMI body mass index
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predicted the duration of postoperative ambulation but
was only marginally associated with survival. Yamashita et
al. [14] used the revised Tokuhashi scoring system to pre-
dict survival in patients with spinal metastases and found
that Frankel grade was not significantly associated with
survival. Kumar et al. [15] studied 87 patients with spinal
metastases from nasopharyngeal cancer and found the
modified Tokuhashi score was the best to predict progno-
sis; however, neurological status had no significant associ-
ation with survival. Quraishi et al. [16] studied the effect
of surgical timing on neurological outcome and survival in
spinal metastases patients and found that earlier surgical
treatment resulted in significantly better neurological out-
comes. However, the timing of surgery did not influence
survival.
Leithner et al. [17] compared 7 preoperative prognos-
tic scoring systems for spinal metastases, including the
Bauer [18], modified Bauer [19], Tokuhashi [2], revised
Tokuhashi [1], Tomita [3], van der Linden [20], and
Sioutos [21] scoring systems. In their analyses, primary
tumor and visceral metastases were the only parameters
significantly associated with survival. Their results did
not show pretreatment neurological status as a prognos-
tic factor; therefore, the authors did not consider paraly-
sis as a predictive of survival [17, 22]. Wibmer et al. [23]
evaluated the same preoperative scoring systems and
found that primary tumor, status of visceral metastases,
and systemic therapy were significantly associated with
survival. Leithner et al. [17] and Wibmer et al. [23] fur-
ther concluded that the Bauer and modified Bauer scor-
ing systems are the most reliable systems for prediction
of survival. The modified Bauer scoring system includes
4 positive prognostic factors: absence of visceral metas-
tases, solitary skeletal metastasis, non-primary lung can-
cer, and primary tumor of the breast or kidney,
lymphoma, or myeloma. It does not include preoperative
neurological palsy as a parameter.
The parameters of the revised Tokuhashi scoring sys-
tem include the patient’s general condition, number of
extraspinal bone metastases, number of metastases in
the vertebral bodies, presence of metastases in the major
internal organs, the primary site of the cancer, and the
presence of palsy. The first 5 parameters are all associated
with disease severity, but palsy score is not. In our study,
the survivals of the Frankel A + B and Frankel C +D
groups were not statistically different. One patient with
preoperative Frankel B status improved to Frankel D post-
operatively and survived for 16 months. One patient with
preoperative Frankel B status improved to Frankel C post-
operatively and survived for 36 months. Patients with pre-
operative Frankel B neurological status can still survive for
a long duration.
These results may be because paralytic condition is not
associated with disease severity, and paralytic condition can
be improved with adequate spinal cord decompression. In a
patient with multiple spine metastases, palsy might be
Fig. 3 A 69-year-old male lung cancer patient with T3, T6 metastases underwent spinal surgery; his preoperative palsy score was 0 (Frankel B).
Axial (a) and sagittal (b) T1-weighted MR images with contrast enhancement demonstrate severe cord compression at T3. His postoperative palsy
score was 1 (Frankel C), and he survived 289 days after spinal surgery
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absent. However, palsy might be noted in a patient with
only 1 vertebral metastasis. A patient with multiple spinal
metastases generally has higher disease severity than a pa-
tient with a single vertebral metastasis. Also, the number of
vertebrae involved and the pattern of spinal cord compres-
sion might be the same in patients with different palsy
score (Figs. 3 and 4). Deterioration of neurological status
might occur in 1 week, and the survival time should not
differ too much in such situation. After adequate surgical
decompression and stabilization, palsy should be reversed
in all patients except those with a neurological status of
Frankel A, or those with a poor overall medical status [24].
Thus, palsy should not be a major prognostic factor in lung
cancer patients with spinal metastasis who underwent
spinal surgery. Patients with paralysis tend to have shorter
survival because of cancer progression, not due to the par-
alysis itself [3]. The duration of survival largely depends on
the disease severity and the ability of other modalities (such
as chemotherapy, targeted therapy, or radiotherapy) to con-
trol the tumor [25–28].
This study has some limitations that should be consid-
ered. First, as a retrospective study from a single center,
several potential biases may exist, including referral bias
and patient characteristics. Second, the sample size was
small. Third, we did not include all parameters in the ana-
lyses. However, this is the first study that focused only on
non-small-cell lung cancer patients with spinal metastases
who underwent spinal surgery. The result of this study
should be valuable in the decision of treatment of non-
small-cell lung cancer patients with spinal metastases.
Conclusions
Preoperative palsy score had no statistically significant
association with survival in non-small-cell lung cancer
patients with spinal metastases who underwent spinal
surgery.
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